In 2010, an FDA advisory panel recommended against approving the drug.

An FDA advisory panel recently voted to recommend the drug's approval.

In May 2012 missing data lead FDA panel to vote against rivaroxaban for acute coronary syndrome.

The FDA panel concluded that overall, Avastin does not help breast cancer patients live substantially longer or enjoy better quality of life with the disease.

The FDA advisory panel voted 17-15 to allow the drug to return to the market despite being found to increase heart risk.

In 2010, an FDA panel recommended banning the use of tanning beds for people under 18 years old.

The FDA panel recommended that patients be required to receive their first dose under medical supervision).

Why do you assume the FDA panel didn't consider the potential harmful effects of repeated dosages?

In 2010 a FDA advisory panel considered the question of how such field trials should be managed.

An FDA advisory panel takes up that question later this week.